Establishment Labs Holdings Inc.
CRFinancials
Valuation Metrics
Establishment Labs Holdings Inc.'s Market Cap is $1.84B. At end of 2025 it was $2.16B. Ranked #2035 of 3,118 in US market (top 65%), #772 of 1,474 on NASDAQ (top 52%), #125 of 203 in Health Care Equipment & Services (top 62%) by Market Cap.
Investment Metrics(as of 2026-10-30)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $1.84B | US#2,035/3,118 Sec#125/203 |
| Revenue | $246M | US#2,495/3,118 Sec#165/203 |
| Net Income | $-39M | US—/3,118 Sec—/203 |
| Total Assets | $352M | US#2,874/3,118 Sec#172/203 |
| Net Assets | $22M | US#2,882/3,118 Sec#189/203 |
| Employees | 1,004 | US#1,977/3,118 Sec#133/203 |
| Value | ||
| P/B | 85.08x | US#2,892/3,118 Sec#192/203 |
| P/S | 7.48x | US#2,572/3,118 Sec#169/203 |
| FCF Yield | -2.29% | US—/3,118 Sec—/203 |
| Profitability | ||
| ROE | -179.99% | US#2,832/3,118 Sec#189/203 |
| ROA | -11.05% | US#2,671/3,118 Sec#158/203 |
| Op. Margin | -7.63% | US#2,492/3,118 Sec#152/203 |
| Revenue Growth | 38.55% | US#317/3,118 Sec#19/203 |
| Financial Health | ||
| Debt Ratio | 1528.76% | US#2,805/3,118 Sec#190/203 |
| Total Debt | $264M | US#2,140/3,118 Sec#115/203 |
| FCF | $-42M | US#2,496/3,118 Sec#175/203 |
| Cash | $71M | US#2,416/3,118 Sec#150/203 |
| Current Ratio | 3.84x | US#594/3,118 Sec#60/203 |
| Performance | ||
| 1Y Return | 22.71% | US#1,058/3,118 Sec#87/203 |
| 1M Return | -2.66% | US#2,020/3,118 Sec#152/203 |
| From 52W High | -36.00% | US#2,196/3,118 Sec#161/203 |
| 1Y MDD | -39.49% | US#1,907/3,118 Sec#118/203 |
| Trading | ||
| Volume | 1,022,403 shares | US#1,469/3,118 Sec#90/203 |
| Trading Value | $65M | US#1,124/3,118 Sec#82/203 |
| Per Share | ||
| EPS | $-1.32 | US—/3,118 Sec—/203 |
| BPS | $0.73 | US#2,721/3,118 Sec#185/203 |
Company Info
Establishment Labs Holdings Inc. operates as a medical technology enterprise specializing in the creation and commercialization of devices for aesthetic and reconstructive plastic surgery. The company is primarily recognized for its silicone gel-filled breast implants, sold under the Motiva Implants brand. Among these are the Motiva Ergonomix and Motiva Ergonomix2, which are distinctive, gravity-sensitive, round, soft silicone-gel-filled implants. Furthermore, Establishment Labs provides the Motiva Flora Tissue Expander for breast tissue and distributes the Puregraft range of products, utilized for the harvesting and redistribution of autologous adipose tissue. The firm markets its offerings across Europe, Latin America, the Asia-Pacific region, and other global markets, leveraging both a direct sales force and exclusive distributors. Founded in 2004, Establishment Labs has its main office situated in Alajuela, Costa Rica.